tetano
Editor, Senior Moderator
Int J Infect Dis
. 2023 Jan 20;S1201-9712(23)00022-X.
doi: 10.1016/j.ijid.2023.01.021. Online ahead of print.
Effect of remdesivir on mortality and the need for mechanical ventilation among hospitalized COVID-19 patients: real-world data from resource-limited country
Revaz Metchurtchlishvili[SUP] 1 [/SUP], Nikoloz Chkhartishvili[SUP] 2 [/SUP], Akaki Abutidze[SUP] 3 [/SUP], Marina Endeladze[SUP] 2 [/SUP], Marine Ezugbaia[SUP] 2 [/SUP], Ana Bakradze[SUP] 2 [/SUP], Tengiz Tsertsvadze[SUP] 3 [/SUP]
Affiliations
Abstract
Background: Georgia introduced remdesivir for the treatment of coronavirus disease 2019 (COVID-19) in December 2020. We evaluated the real-world effect of remdesivir on mortality and the need for mechanical ventilation among COVID-19 inpatients.
Methods: The study included 346 remdesivir recipients and 346 controls not receiving remdesivir selected through propensity score matching based on age, gender, presence of any chronic comorbid condition and oxygen saturation at admission. Factors associated with in-hospital mortality and the need for mechanical ventilation were assessed in multivariable logistic regression model.
Results: The groups were comparable by age, gender, comorbidities and baseline oxygen saturation. Among 346 remdesivir recipients 265 (76.6%) received generic formulation of the drug. Eight (2.3%) patients died in the remdesivirand 18 (5.2%) in the control groups (p=0.046). In the multivariable analysis Remdesivir was associated with non-statistically significant reduced odds of death (OR: 0.39, 95% CI: 0.14-1.04, p=0.06). Significantly fewer patients in the remdesivir group required mechanical ventilation compared to controls: 2.9% vs. 6.4% (p=0.03). Statistically significant difference was maintained in multivariable analysis (OR: 0.40, 95% CI: 1.04-5.60, p=0.04).
Conclusion: Borderline reduction in the odds of death and statistically significant decrease in the need of mechanical ventilation support use of remdesivir in hospitalized COVID-19 patients.
Keywords: COVID-19; Eastern Europe; Georgia; Mechanical Ventilation; Mortality; Remdesivir.
. 2023 Jan 20;S1201-9712(23)00022-X.
doi: 10.1016/j.ijid.2023.01.021. Online ahead of print.
Effect of remdesivir on mortality and the need for mechanical ventilation among hospitalized COVID-19 patients: real-world data from resource-limited country
Revaz Metchurtchlishvili[SUP] 1 [/SUP], Nikoloz Chkhartishvili[SUP] 2 [/SUP], Akaki Abutidze[SUP] 3 [/SUP], Marina Endeladze[SUP] 2 [/SUP], Marine Ezugbaia[SUP] 2 [/SUP], Ana Bakradze[SUP] 2 [/SUP], Tengiz Tsertsvadze[SUP] 3 [/SUP]
Affiliations
- PMID: 36690139
- DOI: 10.1016/j.ijid.2023.01.021
Abstract
Background: Georgia introduced remdesivir for the treatment of coronavirus disease 2019 (COVID-19) in December 2020. We evaluated the real-world effect of remdesivir on mortality and the need for mechanical ventilation among COVID-19 inpatients.
Methods: The study included 346 remdesivir recipients and 346 controls not receiving remdesivir selected through propensity score matching based on age, gender, presence of any chronic comorbid condition and oxygen saturation at admission. Factors associated with in-hospital mortality and the need for mechanical ventilation were assessed in multivariable logistic regression model.
Results: The groups were comparable by age, gender, comorbidities and baseline oxygen saturation. Among 346 remdesivir recipients 265 (76.6%) received generic formulation of the drug. Eight (2.3%) patients died in the remdesivirand 18 (5.2%) in the control groups (p=0.046). In the multivariable analysis Remdesivir was associated with non-statistically significant reduced odds of death (OR: 0.39, 95% CI: 0.14-1.04, p=0.06). Significantly fewer patients in the remdesivir group required mechanical ventilation compared to controls: 2.9% vs. 6.4% (p=0.03). Statistically significant difference was maintained in multivariable analysis (OR: 0.40, 95% CI: 1.04-5.60, p=0.04).
Conclusion: Borderline reduction in the odds of death and statistically significant decrease in the need of mechanical ventilation support use of remdesivir in hospitalized COVID-19 patients.
Keywords: COVID-19; Eastern Europe; Georgia; Mechanical Ventilation; Mortality; Remdesivir.